Press release

DSM showcases safe and effective therapies at CPhI 2019

Kaiseraugst, CH, 03 Sep 2019 15:00 CEST

DSM, stand 40F20, CPhI Worldwide, Frankfurt, Germany, 05-07 November 2019

Royal DSM, a global purpose-led, science-based company focusing on nutrition, health and sustainable living, invites you to discover the evolving role of vitamins and lipids in pharmaceutical applications at CPhI Worldwide 2019. DSM offers high-quality APIs and customized industry expertise - a proven basis for future-proof, agile and safe therapeutic innovation, with the objective of keeping the world’s growing population healthy and improving the quality of life for patients.

Royal DSM is proud to announce its participation at the upcoming CPhI Worldwide 2019, in Frankfurt, Germany. At this year’s exposition, DSM will be introducing WaSo-LC (Water Soluble Lycopersicum Concentrate), a novel, pharmaceutical-grade anti-thrombotic. DSM will also be announcing the results of VITALITY, a highly-anticipated survey of general practitioners, cardiologists and endocrinologists.

As a leader in vitamin and omega-3 fatty acid manufacturing, DSM stands at the forefront of the nutrition and pharmaceutical industry, leveraging its API offerings as proven, safe and innovative compounds. WaSo-LC (Water Soluble Lycopersicum Concentrate) is a novel, plant-derived API with clinically demonstrated blood-clotting inhibitory activity. At CPhI, DSM will share the latest on WaSo-LC’s clinical development program, which aims to bring to market a well-tolerated antiaggregant that addresses a considerable unmet medical need in patients with established cardiovascular risk factors.

DSM remains committed to leveraging and conducting research to better understand patient and prescriber behaviors and needs. Also launching at CPhI: the results of VITALITY, a cross-sectional analysis of over 1,100 healthcare professionals across five countries regarding attitudes and perceptions towards prescribing drug/vitamin combinations. In this proprietary analysis, DSM engaged IQVIA to gain additional insight into provider readiness levels, prescription drivers and overall familiarity with currently available therapeutic options. Ultimately, DSM’s pharmaceutical partners will be able to leverage this data as a key input in the new product development process, thereby facilitating the launch of therapeutic compounds with characteristics which resonate with healthcare professionals and patients alike.

DSM is the first and only company in the world that can provide access to both US Drug Master Files (DMFs) and Certificates of Suitability of Monographs of the European Pharmacopoeia (CEPs) for all 13 vitamins, providing its pharmaceutical partners a competitive advantage by accelerating the registration and market entry process and enabling sustainable, uninterrupted patient access. DSM also has the capacity to produce commercial-scale marine-based lipid API intermediate materials.

DSM’s 400-strong R&D team and global network of regulatory specialists provide the foundational capabilities for timely, safe and effective product co-innovation.

For more information

Nelleke Barning

Global Communications and External Affairs Director
+41 618 158 502